Bli medlem
Bli medlem

Du är här


AroCell signs distributor agreement in India

AroCell continues to expand globally with new distributors. Today, the company has signed a distribution agreement with Hospimedica covering India for the sale of UBC® Rapid.

Hospimedica International Ltd is an Indian company with long experience in the market, covering the entire country through more than ten local sales offices in different regions. The company also represents a plethora of companies from Europe, US, and Asia and already has several products in urology, which makes them well suited to launch UBC® Rapid in the Indian market.

UBC® Rapid is a rapid test intended for detecting bladder cancer, especially in high-risk patients, and monitoring and follow-up after initial diagnosis. The test is clinically documented and is already used today in routine healthcare, for example in Germany.

"We look forward to this new collaboration with Hospimedica for the distribution and marketing of UBC® Rapid in India," says Gunnar Wahlberg, Business Area Manager at AroCell. "We are continuously working to expand into new markets, and India is very exciting for us. Now the first stage of the registration process for approval in India begins".


Anders Hultman, CEO
Phone: +46(0)18 50 30 20

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information;


AroCell signs distributor agreement in India

Författare MFN